CRA was retained on behalf of a pharmaceutical manufacturer to assess the commercial success of drugs indicated for the treatment of severe acne and the nexus between that success and the patents at issue. At issue was the combination use of active ingredients. CRA found commercial success and a nexus between that success and the patents at issue. Although the manufacturer provided patient coupons for copay relief, CRA found that pricing and marketing activity were not undue contributors to commercial success.
Trade Secret Litigation Watch: August 2025
In this Insights, CRA’s Intellectual Property Practice consultants take a closer look at trade secret case filings and developments from the first half of...